Theriva Biologics Profit Margin

Theriva Biologics (TOVX) currently reports a profit margin of -4376.0% as of June 2026. That compares with -19191.56% in the prior-year period — up 77.2% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Theriva Biologics's profit margin history and peer comparisons.

Theriva Biologics's profit margin increased from -19191.56% to -4376.0% — a 77.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Theriva Biologics's profit margin of -4376.0% is lower than the Healthcare sector average of 13.89%. That is roughly 31604.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Theriva Biologics's current -4376.0% should be judged against Healthcare norms (sector average: 13.89%) and against TOVX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -4376.0%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Theriva Biologics, and consider following TOVX for alerts when major investors trade the stock.